Bone Marrow Transplant Center, Department of Oncology Hematology, Ospedale Civile, Pescara, Italy.
UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy.
Bone Marrow Transplant. 2021 May;56(5):1038-1046. doi: 10.1038/s41409-020-01147-z. Epub 2020 Nov 24.
The aim of this retrospective study was to determine the incidence and the clinical outcome of secondary oral cancer (SOC) and to assess potential risk factors in a large cohort of patients (n = 908), who received allogeneic hemopoietic cell transplantation (HCT) either for a malignant (n = 733) or nonmalignant hematologic disease (n = 175). The median follow-up of 438 transplant survivors was 17 years. Twelve patients developed SOC at a median of 13.5 years since HCT and at a median age of 47 years. The 35-year cumulative incidence function of SOC development was 3.47%. In univariate analysis, factors associated with increased incidence of SOC were reduced intensity conditioning and chronic graft-versus-host disease (cGvHD). On multivariate analysis, nonmalignant disease and duration of oral cGvHD ≥15 months were independent risk factors for SOC development. Nonmalignant disease recipients had 3.94× higher than expected rate of SOC (95% confidence interval, 1.50-10.39%, p = 0.0055). Recipients whose oral cGvHD persisted for more than ≥15 months had 58.6× higher than expected rate of SOC (95% confidence interval, 13.3-258.1%), p < 0.0001). This study demonstrates that oral cGvHD and a diagnosis of nonmalignant hematologic disease are strong risk factors in the SOC development.
本回顾性研究旨在确定大样本患者(n=908)中继发性口腔癌(SOC)的发生率和临床结局,并评估潜在的风险因素,这些患者因恶性(n=733)或非恶性血液病(n=175)接受了异基因造血细胞移植(HCT)。438 例移植幸存者的中位随访时间为 17 年。12 例患者在 HCT 后中位 13.5 年且中位年龄 47 岁时发生 SOC。SOC 发展的 35 年累积发生率函数为 3.47%。在单因素分析中,与 SOC 发生率增加相关的因素包括强度降低的调理和慢性移植物抗宿主病(cGvHD)。在多因素分析中,非恶性疾病和口腔 cGvHD 持续时间≥15 个月是非 SOC 发展的独立危险因素。非恶性疾病患者 SOC 的预期发生率高 3.94 倍(95%置信区间,1.50-10.39%,p=0.0055)。口腔 cGvHD 持续时间超过≥15 个月的患者 SOC 的预期发生率高 58.6 倍(95%置信区间,13.3-258.1%,p<0.0001)。本研究表明,口腔 cGvHD 和非恶性血液病诊断是非 SOC 发展的强危险因素。